Classification Changes Impacting the Treatment of LR-MDS
A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.
Video content above is prompted by the following:
- Two recent data presentations have reported on the impact of baseline mutational burden on clinical outcomes for ESAs and luspatercept.
- Please discuss the efficacy of ESAs in patients with very low vs. moderate low to very high IPSS-M risk groups.
- Please discuss the clinical outcomes of luspatercept vs. epoetin alfa from the COMMANDS trial based on IPSS-M risk groups (low, moderate low, moderate high and high) and baseline mutational burden.
Recent Videos
Related Content
Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL
June 27th 2025Article
Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.
Read More
